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Abstract
We explored the potential impact of HPV testing on women’s intentions to be screened for 
cervical cancer in a cohort of Canadian women. Participants aged 25-65 from an ongoing trial 
were sent a questionnaire to assess women’s intentions to be screened for cervical cancer with 
HPV testing instead of Pap smears and to be screened every 4 years or after 25 years of age. We 
created scales for attitudes about HPV testing, perceived behavioural control and direct and 
indirect subjective norms. Demographic data and scales that were significantly different (p<0.1) 
between women who intended to be screened with HPV and those who did not intend were 
included in a stepwise logistic regression model. Of the 2016 invitations emailed, 1538 were 
received, and 981 completed surveys for a response rate of 63% (981/1538). Eighty-four percent 
of women (826/981) responded that they intended to attend for HPV-based cervical cancer 
screening, which decreased to 54.2% when the screening interval was extended, and decreased 
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further to 51.4% when screening start was delayed to age 25. Predictors of intentions to undergo 
screening were attitudes (OR 1.22; 95%CI 1.15, 1.30), indirect subjective norms (OR 1.02; 95%CI 
1.01, 1.03) and perceived behavioural control (OR 1.16; 95% CI 1.10; 1.22). Intentions to be 
screened for cervical cancer with HPV testing decreased substantially when the screening interval 
was extended and screening started at age 25. Use of primary HPV testing may optimize the 
screening paradigm, but programs should ensure robust planning and education to mitigate any 
negative impact on screening attendance rates.
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Introduction
Cervical cancer screening using cytology (the Pap smear) has been an extremely successful 
public health intervention, achieving reductions in incidence of up to 80% where practiced 
effectively 1. However, the Pap smear was introduced over 50 years ago, and despite its 
substantial contributions to cervical cancer reduction, it has limitations as a screening tool. 
Meta-analyses have found that an individual cytology has sensitivity less than 60%2. There 
is now ample evidence that infection with high-risk types of the human papillomavirus (hr-
HPV) is a requisite step for development of cervical cancer and its precursors 3,4. As a 
primary screening tool, cross-sectional studies have shown that hr-HPV testing has higher 
sensitivity and negative predictive value (NPV) for detecting cervical intraepithelial 
neoplasia 2 or worse (CIN2+) than either the conventional or liquid based cytology (LBC), 
but with lower specificity and positive predictive value (PPV)5-10. Therefore, one approach 
for screening would be to use hr-HPV testing as a primary screening test, with cytology 
reserved only for triage of women with positive test results. Several large, international 
randomized controlled trials (RCT) are being conducted in Europe and Canada to evaluate 
the efficacy and effectiveness of HPV testing as the primary screening tool for cervical 
cancer 7,11-20. Data from these trials show that use of hr-HPV as a primary screen improves 
detection of CIN2+, and also prevents more cancers than does cytology 21-23.
Although the United States has used co-testing with HPV and cytology for screening for 
several years24, cervical cancer screening programs across jurisdictions in Canada and 
Europe are now poised to make a substantial paradigm shift, using hr-HPV testing as the 
primary screen for cervical cancer 25-27. However, use of HPV testing as a primary screen 
could lead to changes in the age when cervical cancer screening starts, an extension of the 
interval between screening and has different implications with a positive screening result. 
Because a negative hr-HPV test offers greater assurance to clinicians and screening 
participants that they are not at risk for developing cervical cancer in the near future 8 it has 
been proposed that screening intervals for hr-HPV negative women could be extended safely 
to five years instead of every 2 years28. Given the high HPV prevalence in young women, 
HPV testing in women under 25 will identify many lesions that will ultimately regress; thus, 
cervical cancer screening using hr-HPV testing likely will be delayed until after age 25 and 
possibly even later, to age 30, which is more aligned with current European practices. HPV 
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testing represents a shift from an oncological to a communicable disease paradigm. While 
cytology identifies cellular changes associated with precancerous cervical lesions, HPV 
testing identifies the infection that precipitates these cellular changes. Use of hr-HPV testing 
in screening may require practitioners to inform some women, many of whom have been in 
monogamous relationships, that they are infected with a highly prevalent sexually acquired 
virus. Even though the virus may have been acquired many years prior and HPV is 
qualitatively different from other sexually acquired infections due to its high prevalence and 
long latency, relaying of positive results will create significant challenges both for 
practitioners and for patients. Practitioners will need both to ensure that they set the 
appropriate context for HPV infections, as well as manage emotional responses to positive 
results 29.
Program changes that would occur with the use of HPV testing could influence the 
acceptability and uptake of cervical cancer screening and thus, ultimately, the success of 
screening programs. Prior to moving to primary HPV-based cervical cancer screening, 
clinicians, researchers and policy makers should examine potential impacts of a change from 
cytology to hr-HPV testing on women’s intentions to participate in cervical cancer 
screening. In this study, using the Theory of Planned Behavior 30, we examined Canadian 
women’s intentions to attend cervical cancer screening in the era of primary HPV testing.
Materials and Methods
The primary objective of the study was to determine women’s intentions to be screened with 
HPV testing instead of Pap smears (cytology) for cervical cancer and women’s intentions to 
be screened with HPV at a four year screening interval, with screening starting after 25 
years of age, and to identify variables that predict intentions to undergo HPV testing instead 
of having Pap smears for cervical cancer screening.
Participants and recruitment
Study participants were recruited through the HPV FOCAL trial in British Columbia, 
Canada. HPV-FOCAL is a randomized, controlled, three-armed study conducted in British 
Columbia 19,20 that completed recruitment of over 25,000 women aged 25-65 through the 
province’s population-based cervical cancer screening program at the British Columbia 
Cancer Agency in March 2012. At study exit, all women with email addresses were sent 
invitations to complete an online web-based survey tool. Women were sent two additional 
reminders to complete study questionnaires. Data entered by participants were stored at fluid 
surveys (fluidsurveys.com) and then were automatically populated into an Excel spreadsheet 
for analysis.
Survey instrument
The survey was based in the Theory of Planned Behavior (TPB) 31, which has been used 
extensively to assess screening health behaviours 30. TPB is particularly valuable to describe 
behaviours that are under an individual’s volitional control and identifies intention as the 
most proximate predictor of behaviour. Survey items were developed from literature review 
and feedback from content experts. Surveys were drafted and reviewed by a TPB expert and 
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then pilot tested on ten women in the target demographic. A final revised version of the 
survey was then re-piloted and implemented.
In the survey, women were provided with an introduction to the human papillomavirus, 
including information on transmission, the role of HPV in cervical cancer and the rationale 
for use of primary HPV testing and screening intervals and timing. Demographics and items 
assessing the three specific elements that predict behaviour intentions (attitude towards the 
behaviour, perceived behavioural control, and subjective norms to the behaviour) were 
assessed with seven point Likert scales. Attitudes toward the behaviour are an individual’s 
perspective on the value and utility of behaviour. Subjective norms to behaviour are an 
individual’s belief about how people they care about will view the behavior in question. 
Perceived behavioural control describes an individual’s perception of their ability to control 
the behaviour.
Survey response rate
Survey responses were reviewed for completeness. In the case of duplicate complete 
surveys, the first complete survey was used, and the second survey was discarded. Response 
rate was calculated according to the American Association for Public Opinion Research, 
which is the number of complete surveys divided by the number of returned questionnaires 
plus eligible non-interview 32. Response rate for women who received the survey was the 
number of complete surveys divided by number of complete surveys plus refusal, logged on 
and break off.
Analysis
The primary endpoint was response to the statement ‘I would be willing to have an HPV test 
to screen for cervical cancer instead of a Pap smear’. Women’s intention to be screened with 
HPV for cervical cancer every four years was determined based on response to ‘I would be 
willing to have an HPV test to screen for cervical cancer every four years instead of a Pap 
smear every year’. Women’s intention to be screened with HPV every four years and after 
the age of 25 was determined by response to ‘I would be willing to have an HPV test to 
screen for cervical cancer every four years and after the age of 25 instead of a Pap smear 
every year after becoming sexually active.’ Women responded to a seven point Likert scale 
(strongly disagree to strongly agree). Responses for each were dichotomized, with women 
who responded >4 coded as ‘intending to screen’ and women who responded <= 4 as ‘not 
intending to screen’.
Demographic characteristics of survey non-respondents were compared using data from the 
larger clinical trial. Continuous variables were compared with Student’s t-tests, categorical 
variables were compared with Chi-square and Kruskal-Wallis tests to compare medians, as 
appropriate. Descriptive analyses of demographic characteristics of the survey respondents 
were performed, including mean and median age, marital status, education, sexual history, 
ethnicity and smoking history. Women’s intentions to be screened with HPV for cervical 
cancer as well as overall rates of intentions to be screened every four years and intentions to 
be screened every four years after the age of 25 also were calculated with 95% confidence 
intervals.
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Scale items were analyzed according to methods for Theory of Planned Behavior. Briefly, 
items were re-anchored and re-coded as needed. If items in scales achieved agreement, as 
measured by Cronbach’s alpha >0.5, a composite variable was created and then included in 
the univariate, and where appropriate, multivariate analyses. If scales did not achieve a 
Cronbach’s alpha of >0.5, subscales which did achieve agreement were created and included 
in analyses 33. Beyond assessing the traditional TPB constructs of attitudes, direct and 
indirect subjective norms, and perceived behavioural control, an additional item related to 
the sexual acquisition of HPV was included, as investigators believed this would also be an 
influential factor in women’s intentions to be screened with HPV for cervical cancer. 
Previous studies have identified women’s concerns related to stigma around sexually 
acquired infections, implications of infidelity and the impact of positive HPV results on 
relationships with partners 34. Two items were designed to assess the impact of informing a 
partner about HPV status on decision to receive screening. These items were used to 
determine whether the communicable disease/STI element of HPV would affect women’s 
intentions to have this test.
Demographic characteristics between women who intend to be screened with HPV for 
cervical cancer and those who were not were compared overall and between five year age 
strata, with Chi-square and Student’s t-test as appropriate. Multicollinearity of psychological 
scales that achieved an item correlation with Cronbach’s α >0.5 was assessed with Pearson 
correlation coefficient. If two scales were collinear (>0.8), based on investigator judgment, 
the less influential variable was removed. Following this, overall scale scores and mean 
scores with standard deviations for scale results between those who intended to be screened 
and those who did not intend to be screened were calculated. Mean results with standard 
deviations between scales that had acceptable agreement (Cronbach’s alpha >0.5) and not 
collinear were compared using Student’s t-tests. All demographic (mean age, marital status, 
cultural background, educational background, number of male sexual partners, smoking 
history) and scale variables that achieved p<0.1 in the univariate and bivariate analyses, and 
variables that were identified by the investigators to be important in predicting women’s 
decisions to attend screening based on the comprehensive literature review that preceded 
questionnaire development were entered into the stepwise logistic regression model. We 
created a logistic regression model to predict factors associated with women’s intentions to 
be screened for cervical cancer with HPV testing. The dependent variable for the model was 
‘intention to be screened for cervical cancer with HPV’ (0=did not intend; 1=intended). We 
conducted a direct logistic regression analysis and calculated odds ratios for significant 
variables with 95% confidence intervals to identify variables associated with a women’s 
intention to be screened for cervical cancer with HPV. Analyses were performed using SAS 
9.3.
Results
The survey was conducted between May and September, 2011. Among 2459 women who 
had completed the HPV FOCAL trial, 2016 had email addresses and were sent invitations to 
participate (Figure 1). This group is the eligible population. Of the 2016 eligible women, 
1035 were not surveyed: 478 emails were returned or bounced back (non-contact), 72 
replied that they did not want to participate (refusals), 191 individuals logged onto the 
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survey, but did not start it, and 294 started surveys but did not complete them. 981 returned 
and completed surveys, for an overall response rate of 48.7% (981/2016) for all women and 
63% (981/1538) for women who electronically received the survey.
Survey responders and non-responders did not differ significantly in their socio-
demographic characteristics (Table 1). Survey respondents had a mean age of 45.1 (SD 
10.1); the age range of respondents was 25 to 65 years of age. Over 85% of women had 
more than high school education, and 56.1% reported five or fewer sexual partners in their 
lives. The majority of women were Caucasian, black or South Asian background; 2.4% of 
women were aboriginal. Six percent of women were current smokers, and 36.1% had 
smoked at some time in their lives. 84.2% (95% CI 81.9; 86.5) intended to be screened for 
cervical cancer with HPV. However, women’s intentions to be screened with HPV instead 
of Pap smears for cervical cancer screening decreased from 84.2% to 54.2% (95%CI 51.1; 
57.3) when screening occurred every four years, and decreased further to 51.4% (95%CI 
48.3; 54.5) when screening started at age 25.
Scale consistency was assessed for each construct; most achieved a Cronbach’s alpha of 
>0.6 (Table 2). As there was less robust agreement between the items of the direct subjective 
norms, a scale with two items was included in the analysis, as it had Cronbach’s alpha of 
>0.5.
Of 981 women who completed surveys, 826 reported that they intended to be screened for 
cervical cancer with HPV tests instead of Pap smears (84.2%) (Table 3). There were no 
significant differences between the mean age, age strata, marital status, education level, 
sexual history, cultural background or smoking history of women who intended to be 
screened with HPV tests instead of Pap smears for cervical cancer (p>0.05) compared to 
those who did not intend to be screened with HPV. No scale items had p>0.8 on correlation 
testing, indicating that the variables are measuring non-collinear constructs.
Women who intended to be screened with HPV tests had significantly higher attitudinal 
scores, indicating their belief that HPV testing was more accurate, safe, protective and 
acceptable than Pap smears (p<0.01) (Table 4). They were also significantly more likely to 
report the influence of direct subjective norms on their decisions, with the belief that most 
who are important to them would think they should have an HPV test, and would expect 
them to have an HPV test (P<0.01). Women who intended to be screened with HPV were 
significantly more likely to report the influence of indirect subjective norms as well, 
including the opinions of family physicians, friends, spouse or partner and the British 
Columbia Cancer Agency as important in their decision making to screen (p<0.01). Women 
who were more likely to intend to be screened with HPV testing also reported significantly 
higher rates of perceived behavioural control (p<0.01). Women who intended to be screened 
reported greater comfort sharing results with their partners and were more likely to say that 
partners would be understanding of their HPV results (p=0.05).
Based on the univariate and bivariate analysis, the following independent variables were put 
into the model: psychological scales for attitude; direct subjective norms; indirect subjective 
norm: perceived behavioural control; and contacting partners. No demographic variables 
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achieved significance, and thus were not entered into the model. Odds ratios and 95% 
confidence intervals confirmed that positive attitudes regarding the value of HPV testing 
(OR 1.2; 95%CI 1.1, 1.3) positive indirect subjective norms (OR 1.02; 95% CI 1.01, 1.03) 
and positive behavioural control (OR 1.16; 95%CI 1.10, 1.23) all significantly predict 
women’s intentions to be screened with HPV testing (Table 5).
Discussion
There is increasing evidence demonstrating that cervical cancer screening with primary HPV 
testing coupled with cytology triage is more effective at detecting relevant precancerous 
lesions and decreases cervical cancer incidence20,21. Several jurisdictions, including the 
Netherlands and the province of Ontario, have recommended the use of primary HPV testing 
for cervical cancer 26,27,35. Although neither the Canadian Task Force on Preventive Health 
Care 36 nor the US Preventive Service Task Force37 have yet to recommend primary HPV 
testing for cervical cancer screening, both groups identified that the weight of evidence 
would likely ultimately lead programs towards this recommendation. With this substantive 
change on the horizon in one of the most established screening programs, it is important 
that, prior to introduction of this new technology for screening, broader considerations 
should be included in planning for its implementation. Women’s experiences and their 
willingness to participate in screening if the new technology is adopted should be carefully 
examined. In particular, because of the improvements in the sensitivity and negative 
predictive values of HPV testing compared to cytology, screening programs using primary 
HPV testing would have increased screening intervals and later starting dates. These 
changes, along with the use of a test for a sexually acquired infection, could have unintended 
impacts on the acceptability of cervical cancer screening with primary HPV testing.
In our study, we found that over 80% of women intended to be screened for cervical cancer 
with HPV primary screening. However, women’s intentions to be screened with HPV 
decreased significantly once they were advised of the extended screening interval with HPV 
testing, from 84.2% to 54.2%. Because of improved sensitivity, high negative predictive 
value of HPV compared to Pap screening as well as risk for false positive HPV tests, 
cervical cancer screening using HPV should occur every 4-5 years, not annually as has been 
the case with Pap smears38. When advised that cervical cancer screening with HPV would 
not start until age 25, compared to current starting ages of 18 or soon after sexual debut in 
Canada, women’s intentions to be screened for cervical cancer with HPV remained low at 
51.2%. Programs moving to primary HPV testing must effectively communicate the natural 
history of HPV (emphasizing its prevalence and high rate of regression), added diagnostic 
capabilities and negative predictive value of HPV testing, in order to reassure women about 
the safety of the extended screening interval, and to ensure high acceptability of this 
improved method of cervical cancer screening. In addition, health systems are often poor at 
communicating the risks of over-screening. For cervical cancer, too frequent use of HPV 
testing could lead to unwarranted colposcopies and biopsies, unnecessary anxiety, and 
perhaps create iatrogenic illnesses39, which would be an equally valuable message to convey 
broadly.
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In our logistic regression analyses, the predictors of intention to be screened with HPV were 
overall positive attitudes to HPV, the endorsement and recommendations for HPV testing 
from highly regarded health agencies, health practitioners and individuals in women’s lives 
and women’s ability to gain access to HPV testing. Positive attitudes to HPV testing include 
positive assessments regarding HPV accuracy, safety, ability to protect health and 
acceptability of HPV testing. This indicates that substantial efforts should be made to ensure 
women are aware of the diagnostic attributes of HPV testing, as this is a key element for 
women to understand the safety, accuracy and acceptability of HPV testing. Our findings 
also indicate that opinion leaders for women’s decision-making include groups that have 
established roles in cancer prevention as well as their own practitioners and their peers and 
families. Agencies with cancer prevention, screening and treatment mandates should adopt 
strong messages that endorse and support HPV testing for cervical cancer screening. 
Additionally, education efforts should not be solely targeted at women, but should also 
include their peers and family members, as these individuals are influential agents in 
women’s decisions about screening. Finally, women should understand how they can access 
primary HPV screening, in order for them to plan to receive the testing.
Previous work has found that women report anxiety, distress, and shame when they receive 
positive HPV results 40-42. Women also report concern about communicating test results to 
sexual partners, and about stigma and shame associated with having a sexually transmitted 
infection 38,43. Although these results are illustrative, few studies have examined the impact 
of these emotions of receiving a positive HPV result on women’s intentions to be screened 
for cervical cancer. In our study, we explicitly examined the association of the potential 
need to discuss HPV status with a partner as an influence on intentions to be screened. 
Although significant in the univariate analysis, in the multivariate analysis, contacting and 
communicating HPV status to partners did not emerge as a significant predictor of intentions 
to be screened. This suggests that while important in women’s deliberations for HPV testing, 
ultimately it was not a predictor of women’s intentions to be screened with HPV.
Further research is needed to understand why women are reluctant to have extended 
screening intervals. There are no data about why women are unwilling to have extended 
intervals for primary HPV testing, but in research on Pap smears, women were also reluctant 
to have extended screening intervals; 69% of women reported that they would continue to 
receive annual screening, even if advised it was not required44. In Sirovich’s survey, women 
believed that cost was driving increased intervals between screening, and for HPV testing, 
women may interpret less frequent screening as a poorer quality screening program. Women 
may believe that extended intervals and less frequent screening may miss precancerous 
lesions. Thus, there is a need for comprehensive education for women to improve their 
understanding about the rationales underpinning the move from cytology to HPV testing and 
the differences between the two different technologies, which include a higher sensitivity 
and negative predictive value of HPV compared to cytology, thus decreasing the need for 
frequent screening. It will be critical to determine the optimal communication strategy 
through careful evaluation to ensure women are confident that an extended screening offers 
safe and effective cervical cancer screening. Similarly, changes in age of initiation for 
screening are based on an improved understanding of the natural history of cervical cancer, 
as well as increased awareness of the potential long-term consequences of treatment for 
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precancerous lesions, including preterm labour and low birth weight infants, not on a desire 
to reduce access to screening 39. Messaging that clearly outlines the scientific as opposed to 
economic underpinning of this decision is needed.
Limitations
This study examined women who were part of the provincial screening program in British 
Columbia and had completed participation in a randomized controlled trial 20. Participants 
were emailed invitations, but not all participants had functional email addresses, and not all 
invitees completed responses, leading to a response rate of 63%. Comparison of survey 
respondents and non-respondents showed that they were not significantly different (Table 
1). Survey participants also received information on HPV as part of their participation in the 
study, and thus may be more comfortable with the role of HPV and HPV screening than 
other women. Thus, these study findings are likely to be generalizable to the population of 
women who were part of the provincial screening program and participated in a large 
clinical trial. This study does not capture perspectives of women who did not attend for 
cervical cancer screening, nor the attitudes of women under the age of 25. As this population 
remains a key consideration for cervical cancer prevention, further explorations of this group 
are needed to understand both opportunities to improve uptake with HPV and also to ensure 
there is improved engagement for women who have not attended cervical cancer screening.
Overall, 84.2% of women intended to have cervical cancer screening with HPV instead of 
Pap screening. No demographic characteristics were significantly different among women 
who intended to be screened with HPV. In particular, age, marital status, sexual history, 
smoking history, education and cultural background were not significantly different between 
women who intended to be screened for cervical cancer with HPV and those who did not. 
There was also no difference between age strata for women who intended to be screened 
with HPV and those who did not. This is in contrast to several previous studies, which 
identified differing anxiety and concerns about HPV and willingness to have HPV-based 
tests, depending on age 29,45,46, and cultural background34. In particular, previous studies 
reported certain cultural groups identified concerns about the sexual nature of the infection, 
implications for fidelity and relationships and the need for disclosure34,38. Regardless, this 
has relevance for programming. One might expect women who have different educational or 
cultural backgrounds to be more or less reluctant to move to a different type of screening; 
particularly one with a communicable disease overtone, and that this ultimately could affect 
on willingness to be screened.
This study is one of the first to identify the potential impact of a transition to HPV primary 
screening from cytology on uptake of cervical cancer screening. In a highly motivated 
population, although over 80% of women were willing to be screened with HPV, women’s 
intentions to be screened for cervical cancer decreased to 54% when they were made aware 
of extended screening intervals. Jurisdictions considering the use of primary HPV screening 
need to ensure comprehensive education program for women, to assure them of the safety 
and rationale for primary HPV screening and to mitigate any potential negative impact on 
screening attendance rates.
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Appendix 1. Information sheet provided to survey recipients
The human papillomavirus (HPV) is a common virus that can infect the cervix (part of a 
woman’s womb). It is now known to be the cause of cervical cancer. Women develop HPV 
infections in the cervix after having sexual activity with a partner who is infected with HPV. 
However, HPV is so common that over 75% of sexually-active women will have an HPV 
infection of their cervix sometime during their life. Most women who find out they have an 
HPV infection in the cervix after the age of 30, were infected with HPV years before. Over 
90% of women who are infected with HPV in the cervix get rid of the infection naturally. It 
is only women who have longstanding infections with certain types of HPV who may be at 
risk for developing cervical cancer. Women may not have known it in the past, but it is these 
same HPV infections that are the most common reason for abnormal Pap smears.
Right now in BC, women start cervical cancer screening once they become sexually active. 
We now know that testing for HPV infections in the cervix is more accurate than the Pap 
smear for predicting whether or not a woman will develop cervical cancer.
References
1. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of 
human papillomavirus infection. CMAJ. 2001; 164:1017–1025. [PubMed: 11314432] 
2. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselbad V, Hickey JD. Accuracy of the 
Papanicoloau test in screening for and follow-up of cervical cytologic abnormalities: a systematic 
review. Annals of Internal Medicine. 2000; 132:810–819. [PubMed: 10819705] 
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, 
Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer 
worldwide. J Pathol. 1999; 189:12–19. [PubMed: 10451482] 
4. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, 
International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. 
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl 
J Med. 2003; 348:518–527. [PubMed: 12571259] 
5. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human 
papillomavirus testing. Cancer. 2007; 111:145–153. [PubMed: 17487850] 
6. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical 
cancer precursors. Cancer Epidemiol Biomarkers Prev. 2000; 9:945–951. [PubMed: 11008913] 
7. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, 
Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P. Management 
of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 
2003; 362:1871–1876. [PubMed: 14667741] 
8. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, 
Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, Joint European CS. Long 
term predictive values of cytology and human papillomavirus testing in cervical cancer screening: 
joint European cohort study. BMJ. 2008; 337:a1754. [PubMed: 18852164] 
9. Franco EL. Chapter 13: Primary screening of cervical cancer with human papillomavirus tests. J 
Natl Cancer Inst Monogr. 2003; 31:89–96. [PubMed: 12807951] 
10. Franco EL, Ferenczy A. Is HPV testing with cytological triage a more logical approach in cervical 
cancer screening? Lancet Oncology. 2006; 7:527–529. [PubMed: 16814203] 
Ogilvie et al. Page 10













11. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine cervical screening with primary 
HPV testing and cytology triage protocol in a randomised setting. British Journal of Cancer. 2005; 
93:862–867. [PubMed: 16189520] 
12. Kotaniemi-Talonen L, Anttila A, Malila N, Tarkkanen J, Laurila P, Hakama M, Nieminen P. 
Screening with a primary human papillomavirus test does not increase detection of cervical cancer 
and intraepithelial neoplasia 3. European Journal of Cancer. 2008; 44:565–571. [PubMed: 
18248809] 
13. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, 
Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, et al. Human 
papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and 
cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007; 
370:1764–1772. [PubMed: 17919718] 
14. Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, Sargent A, Peto J, 
ARTISTIC Trial Study Group. HPV testing in routine cervical screening: cross sectional data from 
the ARTISTIC trial. British Journal of Cancer. 2006; 95:56–61. [PubMed: 16773068] 
15. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Forslund 
O, Hansson BG, Rylander E, Dillner J. Human papillomavirus and Papanicolaou tests to screen for 
cervical cancer. N Engl J Med. 2007; 357:1589–1597. [PubMed: 17942872] 
16. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee 
F, Franco EL, Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus 
DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357:1579–
1588. [PubMed: 17942871] 
17. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla PP, Del Mistro A, Gillio-Tos A, Minucci 
D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, et al. Results at recruitment from a 
randomized controlled trial comparing human papillomavirus testing alone with conventional 
cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008; 100:492–501. 
[PubMed: 18364502] 
18. Giorgi-Rossi P, Segnan N, Zappa M, Naldoni C, Zorzi M, Confortini M, Merito M, Cuzick J, 
Ronco G. The impact of new technologies in cervical cancer screening: results of the recruitment 
phase of a large randomised controlled trial from a public health perspective. International Journal 
of Cancer. 2007; 121:2729–2734.
19. Ogilvie GS, vanNiekerk D, Krajden M, Martin RE, Ehlen TG, Ceballos K, Smith LW, Kan L, 
Cook DA, Peacock S, Stuart GC, Franco EL, Coldman AJ. A randomized controlled trial of 
Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary 
results (HPV FOCAL Trial). BMC Cancer. 2010:10. [PubMed: 20064265] 
20. Ogilvie GS, Krajden M, van Niekerk DJ, Martin RE, Ehlen TG, Ceballos K, Smith LW, Kan L, 
Cook DA, Peacock S, Stuart GC, Franco EL, Coldman AJ. Primary cervical cancer screening with 
HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled 
trial - the HPV FOCAL Study. Br J Cancer. 2012; 107:1917–1924. [PubMed: 23169286] 
21. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla PP, Del Mistro A, Ghiringhello B, 
Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, et al. Efficacy of human 
papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial 
neoplasia: a randomised controlled trial. Lancet Oncol. 2010; 11:249–257. [PubMed: 20089449] 
22. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A. Age-
specific evaluation of primary human papillomavirus screening vs conventional cytology in a 
randomized setting. J Natl Cancer Inst. 2009; 101:1612–1623. [PubMed: 19903804] 
23. Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P, Tarkkanen J, Malila N, 
Nieminen P. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ 
in primary HPV DNA screening with cytology triage: randomised study within organised 
screening programme. BMJ. 2010; 340:c1804. [PubMed: 20423964] 
24. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney 
W, Moscicki AB, Noller KL, Wheeler CM, et al. American Cancer Society Guideline for human 
papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA: a Cancer 
Journal for Clinicians. 2007; 57:7–28. [PubMed: 17237032] 
Ogilvie et al. Page 11













25. Murphy J, Kennedy E, Dunn S, McLachlin M, Fung Kee Fung M, Gzik D, Shier M, Paszat L. HPV 
testing in Primary Cervical Screening: A Systematic Review and Meta-Analysis. J Obstetrics and 
Gynecology of Canada. 2012; 34:443–452.
26. Murphy J, Kennedy EB, Dunn S, McLachlin CM, Fung Kee FM, Gzik D, Shier M, Paszat L. 
Cervical screening: a guideline for clinical practice in Ontario. J Obstet Gynaecol Can. 2012; 
34:453–458. [PubMed: 22555138] 
27. Health Council of the Netherlands. Population screening for cervical cancer. Health Council of the 
Netherlands; The Hague: 2011. Publication no. 2011/07
28. Franceschi S, Cuzick J, Herrero R, Dillner J, Wheeler CM. EUROGIN 2008 roadmap on cervical 
cancer prevention. Int J Cancer. 2009; 125:2246–2255. [PubMed: 19521965] 
29. Huang AJ, Perez-Stable EJ, Kim SE, Wong ST, Kaplan CP, Walsh JM, Iwaoka-Scott AY, Sawaya 
GF, et al. Preferences for human papillomavirus testing with routine cervical cancer screening in 
diverse older women. Journal of General Internal Medicine. 2008; 23:1324–1329. [PubMed: 
18506546] 
30. Ajzen. The theory of planned behavior. Organizational Behavior and Human Decision. 1991; 
50:179–211.
31. Hankins M, French D, Horne R. Statistical Guidelines for Studies of the Theory of Reasoned 
Action and the Theory of Planned Behaviour. Psychology and Health. 2000; 15:151–161.
32. The American Association for Public Opinion Research. Final disposition of case codes and 
outcome rates for surveys. 7th edition. AAPOR; 2011. 
33. Francis, JJ.; Eccles, MP.; Johnston, M.; Walker, A.; Grimshaw, J.; Foy, R.; Kaner, EFS.; Smith, L.; 
Bonetti, D. Constructing Questionnaires based on the theory of planned behaviour: A manual for 
health services researchers. Quality of Life and Management of Living Resources. University of 
Newcastle; 2004. 
34. McCaffery K, Forrest S, Waller J, Desai M, Szarewski A, Wardle J. Attitudes towards HPV 
testing: a qualitative study of beliefs among Indian, Pakistani, African-Caribbean and white British 
women in the UK. Br J Cancer. 2003; 88:42–46. [PubMed: 12556957] 
35. Murphy J, Kennedy EB, Dunn S, McLachlin CM, Fung Kee FM, Gzik D, Shier M, Paszat L. HPV 
testing in primary cervical screening: a systematic review and meta-analysis. J Obstet Gynaecol 
Can. 2012; 34:443–452. [PubMed: 22555137] 
36. Canadian Task Force on Preventive Health Care. Recommendations on screening for cervical 
cancer. Canadian Medical Association Journal. 2013 DOI:10.1503/cmaj.121505. 
37. Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and 
human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. 
Preventive Services Task Force. Ann Intern Med. 2011; 155:687–5. [PubMed: 22006930] 
38. Fernandez ME, McCurdy SA, Arvey SR, Tyson SK, Morales-Campos D, Flores B, Useche B, 
Mitchell-Bennett L, Sanderson M. HPV knowledge, attitudes, and cultural beliefs among Hispanic 
men and women living on the Texas-Mexico border. Ethn Health. 2009; 14:607–624. [PubMed: 
19953392] 
39. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric 
outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: 
systematic review and meta-analysis. Lancet. 2006; 367:489–498. [PubMed: 16473126] 
40. Waller J, McCaffery K, Kitchener H, Nazroo J, Wardle J. Women’s experiences of repeated HPV 
testing in the context of cervical cancer screening: a qualitative study. Psychooncology. 2007; 
16:196–204. [PubMed: 16858719] 
41. Waller J, Marlow LA, Wardle J. The association between knowledge of HPV and feelings of 
stigma, shame and anxiety. Sex Transm Infect. 2007; 83:155–159. [PubMed: 17098767] 
42. Waller J, Marlow LA, Wardle J. Anticipated shame and worry following an abnormal Pap test 
result: the impact of information about HPV. Prev Med. 2009; 48:415–419. [PubMed: 19059280] 
43. Daley EM, Perrin KM, McDermott RJ, Vamos CA, Rayko HL, Packing-Ebuen JL, Webb C, 
McFarlane M. The psychosocial burden of HPV: a mixed-method study of knowledge, attitudes 
and behaviors among HPV+ women. J Health Psychol. 2010; 15:279–290. [PubMed: 20207671] 
44. Sirovich BE, Woloshin S, Schwartz LM. Screening for cervical cancer: will women accept less? 
Am J Med. 2005; 118:151–158. [PubMed: 15694900] 
Ogilvie et al. Page 12













45. Anhang R, Wright TC Jr. Smock L, Goldie SJ. Women’s desired information about human 
papillomavirus. Cancer. 2004; 100:315–320. [PubMed: 14716766] 
46. Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A. Psychological impact of human 
papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 
cross sectional questionnaire study. BMJ. 2004; 328:1293. [PubMed: 15166066] 
Ogilvie et al. Page 13













Impact statement: Despite evidence for primary HPV testing, there is no published data 
on whether women will accept HPV testing for cervical cancer screening. In this large 
study, we find women are willing to be screened with HPV, but acceptability decreases 
significantly when women are advised about the extended screening interval and the later 
start of screening with HPV-based screening. Study findings will have substantial 
influence globally as countries consider changing to HPV based cervical cancer 
screening.
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Study flowchart and participant disposition
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Table 1










Overall 2016 981 1035
Age,
Recruitment








Education Missing 130 130 0.2330

















Missing 151 151 0.8514
0 4(0.2%) 1(0.1%) 3(0.3%)
1 362(19.4%) 185(18.9%) 177(20.0%)
2 to 5 693(37.2%) 364(37.1%) 329(37.2%)
6 to 10 408(21.9%) 221(22.5%) 187(21.2%)
11 to 50 376(20.2%) 198(20.2%) 178(20.1%)
>50 22(1.2%) 12(1.2%) 10(1.1%)
Cultural
background
Missing 128 128 0.2879
Chinese 175(9.3%) 81(8.3%) 94(10.4%)




Smoke, Now Missing 188 188 0.1908
No 1707(93.4%) 923(94.1%) 784(92.6%)
Yes 121(6.6%) 58(5.9%) 63(7.4%)
Smoke, Ever Missing 184 184 0.4382
No 1156(63.1%) 627(63.9%) 529(62.2%)
Yes 676(36.9%) 354(36.1%) 322(37.8%)
*
Pearson’s Chi Square; Student’s t-test;
†
Kruskal-Wallis
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Table 2
Characteristics of scale items: Correlation by Cronbach’s alpha
Screening
Concepts




A1: Having an HPV test to screen for cervical
cancer instead of a Pap smear would be:
• Accurate
• Safe







A20. Having an HPV test to screen for cervical
cancer every four years instead of a Pap smear
every year would be:
• Accurate
• Safe









A22. Having an HPV test to screen for cervical
cancer every four years and after age of 25
instead of a Pap smear every year would be:
• Accurate
• Safe






SND 2: Most people who are important to me would
think that I should have an HPV test to screen for
cervical cancer instead of a Pap smear
SND3: People who are important to me would
expect me to have an HPV test to screen for
cervical cancer instead of a Pap smear SND4. I
would feel under social pressure to have an HPV
test to screen for cervical cancer instead of a Pap
smear
SND4: I would feel under social pressure to have an













SNI5. My family physician would think that I should
have an HPV test to screen for cervical cancer
instead of a Pap smear
SNI6. What my family physician thinks is important
to me
SNI7. My friends would think that I should have an
HPV test to screen for cervical cancer instead of a
Pap smear
SNI8. What my friends think is important to me
SNI9. My spouse/partner would think that I should
have an HPV test to screen for cervical cancer
instead of a Pap smear
SNI10. What my spouse/partner thinks is important
to me
SNI11. The BC Cancer Agency would recommend
that I should have an HPV test to screen for cervical
cancer instead of a Pap smear
SNI12. What the BC Cancer Agency recommends is
important to me
SNI5-SNI12 0.823
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Screening
Concepts




CP13. If I had a cervical cancer screening result that
showed I had an HPV infection, I would feel
comfortable sharing the results with my partner(s)






PBC15. I am confident that I could have an HPV
test to screen for cervical cancer instead of a Pap
smear
PBC16. For me to have an HPV test to screen for
cervical cancer instead of a Pap smear would be
PBC17. Whether or not I would have an HPV test to
screen for cervical cancer instead of a Pap smear
would be entirely up to me
PBC18. How much control would you have over
whether you had an HPV test to screen for cervical
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Table 3
Univariate and bivariate comparisons between demographic characteristics of women who intend and do not 













screened with HPV 826(84.2%) 155(15.8%) 0
Age Mean (Standard deviation) 44.9 (10.1) 45.1 (9.2) 0.8874
Age 25-29 67 (83.8) 13 (16.3) 0.542
30-34 65 (86.7) 10 (86.7)
35-39 124 (86.1) 20 (13.9)
40-44 151 (82.5) 32 (17.5)
45-49 142 (84.0) 27 (16.0)
50-54 111 (81.6) 25 (18.4)
55-59 94 (81.0) 22 (19.0)
60-64 64 (91.4) 6 (8.6)
65+ 8 (100) 0 (0)
Marital Status Divorced 88(10.7%) 20(12.9%) 0.7427
Common Law/Married 581(70.3%) 108(69.7%)
Never Married 95(11.5%) 17(11.0%)
Widowed 7(0.8%)
Did not Answer/Missing 55(6.7%) 10(6.5%)
Education <High School 9(1.1%) 2(1.3%) 0.6839
High School (Complete) 105(12.7%) 17(11.0%)
Trade/College/University(Incomplete) 292(35.4%) 64(41.3%)
University graduate 264(32.0%) 47(30.3%)
University Advanced Degree 156(18.9%) 25(16.1%)
Education:
Combined High School or Less 114(13.8%) 19(12.3%) 0.6065
More than High school 712(86.2%) 136(87.7%)
Sexual Partners -
Ever 0 1(0.1%) 0.6869
1 155(18.8%) 30(19.4%)
2 to 5 315(38.1%) 49(31.6%)
6 to 10 180(21.8%) 41(26.5%)
11 to 50 165(20.0%) 33(21.3%)
>50 10(1.2%) 2(1.3%)
Cultural background Chinese 71(8.6%) 10(6.5%) 0.3236
Aboriginal 18(2.2%) 6(3.9%)
Caucasian and other 737(89.2%) 139(89.7%)
Smoke, Ever No 527(63.8%) 100(64.5%) 0.865
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Table 4









Do not intend to
screen
(PI19<=4)
Mean (SD) P Value*
Attitudes to HPV testing (A1) 25.7 (3.7) 26.5 (2.4) 21.2 (5.7) <.0001
Subjective norms, Direct (SND2-3) 11.0 (2.6) 11.4 (2.3) 8.8 (2.6) <.0001
Subjective norms, Indirect (SNI5-12) 34.8 (31.9) 40.7 (28.9) 3.3 (28.8) <.0001
Perceived Behavioural Control
(PBC 15-18)
23.4 (4.1) 24.1 (3.7) 19.6 (4.1) <.0001
Contacting Partners
(CP13-14)
12.6 (2.2) 12.7 (2.2) 12.2 (2.6) 0.0555
*
Student’s t-test
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Table 5
Predictors of women’s intentions to receive cervical cancer screening with primary human papillomavirus 
testing using multivariate logistic regression
Variable Name Odds Ratio 95% Confidence
Interval
Attitudes to HPV (A1) 1.224 1.153; 1.301
Indirect subjective norms (SNI5-12) 1.022 1.014; 1.031
Perceived behavioural control (PBC 15-18) 1.158 1.095; 1.225
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